— Company study aims to determine efficacy of diabetes treatment
Las Vegas, Nevada, July 7, 2015, Cell MedX Corp. (OTCQB: CMXC) (“Cell MedX” or the “Company”) is pleased to announce that efforts are underway to commence clinical trials of its innovative and proprietary technology branded under the trade name e-Balance. Designed for the treatment of diabetes, the intent of the upcoming trials is to accurately measure and quantify e-Balance’s ability to alter key metabolic pathways targeting improved blood sugar control.
Dr. John Sanderson, Cell MedX Chief Medical Officer, is assembling a team of nurses and clinicians as well as a cohort of volunteer diabetic patients in preparation for startup of phase one trials in Irvine, CA slated for late July. The hardware package to be used in the study has arrived in California with a duplicate package required for supplementary testing anticipated to arrive prior to the end of the month.
The clinical medical teams are being mobilized to work with the volunteer patients several times per week according to the protocols developed by Dr. Sanderson. The end points are intended to measure reductions in HB1AC levels (and related factors) and will be used to determine commercial viability and parameters to be incorporated into the proposed e-Balance self-management diabetic home care devices. A series of phased activities focused on the near-term development of e-Balance proto-types are anticipated to commence concurrent to the clinical trials.
Cell MedX President and CEO Mr. Frank McEnulty comments, “We are thrilled and delighted to begin readying what may be the most important phase in the growth of the Company. We firmly believe that our technology can aid sufferers of diabetes and now we are entering into trials through which we can quantify to what degree our technology can help these individuals. We also plan to begin reviewing the likelihood of potentially related technological impacts on other diseases and conditions as part of our ongoing studies. From our perspective, the upcoming weeks and months ahead look very exciting and we plan to document and share each step of the process with our stakeholders, vendors, partners and the investment community as we seek to execute on what we see as an emerging growth opportunity.”
About Cell MedX Corp (OTCQB: CMXC)
Cell MedX Corp. is an early development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. Through its wholly owned subsidiary, Avyonce Cosmedics Inc., Cell MedX Corp. is engaged in reselling and marketing of technology and equipment to the worldwide wellness industry as well as providing continuing education to health care professionals. For more information go to: www.cellmedx.comand visit us on Facebook.
On behalf of the Board of Directors of Cell MedX Corp.
Frank McEnulty
Chief Executive Officer and President.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company’s e-balance Technology is still in development. The Company does not currently have any commercially marketable products based on the e-balance Technology, and there is no assurance that the Company will be successful in its development efforts. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
Source
Cell MedX Corp.
For further information visit: www.cellmedx.com.
Or phone: 1-844-238-2692